A carregar...
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation
BACKGROUND: Exenatide (EXT), the first glucagon-like peptide-1 receptor agonist, has been approved as an adjunctive therapy for patients with type 2 diabetes. Due to EXT’s short half-life, EXT must be administrated by continuous subcutaneous (s.c.) injection twice daily. In previous studies, many st...
Na minha lista:
| Publicado no: | Daru |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583966/ https://ncbi.nlm.nih.gov/pubmed/28870261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40199-017-0186-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|